Shares of Galapagos NV (NASDAQ:GLPG) have been given an average rating of “Buy” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $115.17.
Several research analysts have recently weighed in on the company. BidaskClub cut Galapagos from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Cowen Inc reaffirmed a “buy” rating on shares of Galapagos in a research report on Thursday, August 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Galapagos in a research report on Thursday, August 10th. Stifel Nicolaus raised Galapagos from a “hold” rating to a “buy” rating and upped their price objective for the stock from $83.00 to $101.00 in a research report on Friday, August 11th. Finally, Nomura upped their price objective on Galapagos from $108.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, August 11th.
Galapagos (NASDAQ GLPG) traded up $0.28 during midday trading on Friday, reaching $92.23. The company had a trading volume of 35,122 shares, compared to its average volume of 86,342. Galapagos has a fifty-two week low of $57.16 and a fifty-two week high of $104.12.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Advisors Preferred LLC bought a new stake in Galapagos in the third quarter valued at approximately $105,000. Acadian Asset Management LLC bought a new stake in Galapagos in the second quarter valued at approximately $166,000. New York State Common Retirement Fund bought a new stake in Galapagos in the second quarter valued at approximately $166,000. Pacad Investment Ltd. bought a new stake in Galapagos in the second quarter valued at approximately $168,000. Finally, Envestnet Asset Management Inc. raised its stake in Galapagos by 156.6% in the third quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 1,063 shares during the period. 21.42% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This article was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://transcriptdaily.com/2017/11/26/galapagos-nv-glpg-receives-consensus-recommendation-of-buy-from-analysts.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.